166 related articles for article (PubMed ID: 38708599)
1. Inhibitor eradication and treatment for acquired hemophilia A.
Franchini M; Focosi D
Expert Rev Hematol; 2024 Jun; 17(6):233-240. PubMed ID: 38708599
[TBL] [Abstract][Full Text] [Related]
2. Innovative Therapies for Acquired Hemophilia A.
Franchini M; Focosi D
Semin Thromb Hemost; 2024 Feb; ():. PubMed ID: 38395066
[TBL] [Abstract][Full Text] [Related]
3. The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.
D'arena G; Grandone E; Di Minno MN; Musto P; Di Minno G
Blood Transfus; 2016 May; 14(2):255-61. PubMed ID: 26509821
[TBL] [Abstract][Full Text] [Related]
4. Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?
Franchini M; Schiavulli M; Liumbruno GM
Expert Rev Hematol; 2021 Mar; 14(3):263-270. PubMed ID: 33655810
[No Abstract] [Full Text] [Related]
5. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
[TBL] [Abstract][Full Text] [Related]
6. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.
Sakurai Y; Takeda T
J Immunol Res; 2014; 2014():320674. PubMed ID: 24741588
[TBL] [Abstract][Full Text] [Related]
7. Acquired hemophilia A: a review of recent data and new therapeutic options.
Franchini M; Vaglio S; Marano G; Mengoli C; Gentili S; Pupella S; Liumbruno GM
Hematology; 2017 Oct; 22(9):514-520. PubMed ID: 28441921
[TBL] [Abstract][Full Text] [Related]
8. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A.
Hunt S; Robertson J; Conn J; Casey J; Royle J; Collins J; Hourigan M; Richmond J; Yang Wang T; Mills A; Mason J
Eur J Haematol; 2022 Jan; 108(1):28-33. PubMed ID: 34528303
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
Pasca S; Zanon E; Mannucci PM; Peyvandi F
Blood Transfus; 2023 Nov; 21(6):549-556. PubMed ID: 36795341
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan.
Ogawa Y; Yanagisawa K; Uchiumi H; Ishizaki T; Mitsui T; Gouda F; Ieko M; Ichinose A; Nojima Y; Handa H
Int J Hematol; 2017 Jul; 106(1):82-89. PubMed ID: 28299631
[TBL] [Abstract][Full Text] [Related]
11. An extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A.
Barg AA; Livnat T; Kenet G
Thromb Res; 2017 Mar; 151 Suppl 1():S82-S85. PubMed ID: 28262242
[TBL] [Abstract][Full Text] [Related]
12. Acquired haemophilia A: a 2013 update.
Franchini M; Mannucci PM
Thromb Haemost; 2013 Dec; 110(6):1114-20. PubMed ID: 24008306
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Severe Acquired Haemophilia A with Immunosuppressive Agent: A Case Report of One Patient.
Škunca Ž; Peraica AP
Coll Antropol; 2016 Jun; 40(2):139-43. PubMed ID: 29139630
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of acquired hemophilia A associated with immune thrombocytopenia and joint hemarthrosis: A case report and literature review.
Wei F
Medicine (Baltimore); 2018 Sep; 97(38):e12044. PubMed ID: 30235659
[TBL] [Abstract][Full Text] [Related]
15. Acquired hemophilia: a case report and review of the literature.
Mulliez SM; Vantilborgh A; Devreese KM
Int J Lab Hematol; 2014 Jun; 36(3):398-407. PubMed ID: 24750687
[TBL] [Abstract][Full Text] [Related]
16. Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.
Ogawa Y; Yanagisawa K; Naito C; Uchiumi H; Ishizaki T; Shimizu H; Gohda F; Ieko M; Ichinose A; Handa H
Int J Hematol; 2020 Apr; 111(4):544-549. PubMed ID: 31939075
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in the treatment of acquired factor VIII inhibitors.
Wiestner A; Cho HJ; Asch AS; Michelis MA; Zeller JA; Peerschke EI; Weksler BB; Schechter GP
Blood; 2002 Nov; 100(9):3426-8. PubMed ID: 12384448
[TBL] [Abstract][Full Text] [Related]
18. Should emicizumab be used in patients with acquired hemophilia A?
Tiede A; Kemkes-Matthes B; Knöbl P
J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.
Lévesque H; Viallard JF; Houivet E; Bonnotte B; Voisin S; Le Cam-Duchez V; Maillot F; Lambert M; Liozon E; Hervier B; Fain O; Guillet B; Schmidt J; Luca LE; Ebbo M; Ferreira-Maldent N; Babuty A; Sailler L; Duffau P; Barbay V; Audia S; Benichou J; Graveleau J; Benhamou Y;
Thromb Res; 2024 May; 237():79-87. PubMed ID: 38555718
[TBL] [Abstract][Full Text] [Related]
20. Acquired haemophilia syndrome: pathophysiology and therapy.
Elezović I
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():64-8. PubMed ID: 20229686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
